Drugs targeting key regulatory genes in metabolism, Enasidenib and Ivosidenib, isocitrate dehydrogenase (IDH) inhibitors as a case in point, have been developed to treat AML more effectively than conventional regimen (DiNardo et al., 2018; Stein et al., 2019). The gene discussed is IDH2; the disease is acute myeloid leukemia.